Colorectal Cancer — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Offer nivolumab-ipilimumab; reserve pembrolizumab for patients unable to receive it
NG151 recommends nivolumab plus ipilimumab after fluoropyrimidine-based combination chemotherapy in MSI-high or dMMR metastatic colorectal cancer. Pembrolizumab is recommended at this treatment position only when nivolumab-ipilimumab cannot be used. The alternatives either ignore molecular selection, invent an unappraised sequence or incorrectly restrict immunotherapy to untreated disease.
Reference: NICE NG151 colorectal cancer recommendations (Updated with 2025–2026 technology appraisals): https://www.nice.org.uk/guidance/ng151/chapter/Recommendations